Literature DB >> 17302913

Palatability of angiotensin II antagonists among nephropathic children.

Chiara M Meier1, Giacomo D Simonetti, Silvia Ghiglia, Emilio Fossali, Patrizia Salice, Costanzo Limoni, Mario G Bianchetti.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Among children, medication palatability is crucial for adherence to therapeutic regimen. * Several studies have measured the palatability of antimicrobial suspensions in paediatric patients by means of a visual analogue scale palatability score. WHAT THIS STUDY ADDS: * This is the first analysis comparing the taste and smell acceptability of angiotensin II receptor blockers among paediatric patients with kidney disease. * From the perspective of the child with kidney disease, the taste of pulverized candesartan is significantly superior to that of pulverized irbesartan, losartan, telmisartan or valsartan. AIM: Angiotensin II receptor blockers are widely prescribed in kidney disease. Among children, medication palatability is crucial for adherence.
METHODS: Taste and smell acceptability of five angiotensin II receptor blockers were compared among 21 nephropathic children using a visual analogue scale palatability score.
RESULTS: The score assigned to pulverized tablets of candesartan cilexetil was significantly higher than that assigned to pulverized tablets of irbesartan, losartan, telmisartan and valsartan.
CONCLUSIONS: From the perspective of the nephropathic child, the taste of pulverized candesartan cilexetil is superior to that of irbesartan, losartan, telmisartan or valsartan.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302913      PMCID: PMC2000746          DOI: 10.1111/j.1365-2125.2006.02814.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.

Authors:  Lorenzo M D Franscini; Rodo O Von Vigier; Roger Pfister; Carmen Casaulta-Aebischer; Emilio Fossali; Mario G Bianchetti
Journal:  Am J Hypertens       Date:  2002-12       Impact factor: 2.689

Review 2.  "Why do they do that?" The compliance conundrum.

Authors:  Thomas E Nevins
Journal:  Pediatr Nephrol       Date:  2005-05-24       Impact factor: 3.714

3.  Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

Authors:  Giacomo D Simonetti; Rodo O von Vigier; Martin Konrad; Mattia Rizzi; Emilio Fossali; Mario G Bianchetti
Journal:  Pediatr Nephrol       Date:  2006-06-27       Impact factor: 3.714

4.  A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years.

Authors:  Cynthia Holas; Yi-Lin Chiu; Gerard Notario; Dolores Kapral
Journal:  Clin Ther       Date:  2005-12       Impact factor: 3.393

Review 5.  Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Authors:  Z H Israili
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

Review 6.  Formulation of medicines for children.

Authors:  Tony Nunn; Julie Williams
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

7.  Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.

Authors:  Demetrius Ellis; Michael L Moritz; Abhay Vats; Janine E Janosky
Journal:  Am J Hypertens       Date:  2004-10       Impact factor: 2.689

8.  A double-blind, dose-response study of losartan in hypertensive children.

Authors:  Shahnaz Shahinfar; Francisco Cano; Beth A Soffer; Tuli Ahmed; Emanuela P Santoro; Zhongxin Zhang; Gilbert Gleim; Kenneth Miller; Beth Vogt; Jeffrey Blumer; Igor Briazgounov
Journal:  Am J Hypertens       Date:  2005-02       Impact factor: 2.689

9.  Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.

Authors:  Demetrius Ellis; Abhay Vats; Michael L Moritz; Susanne Reitz; Mary Jo Grosso; Janine E Janosky
Journal:  J Pediatr       Date:  2003-07       Impact factor: 4.406

10.  Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.

Authors:  Anne C Gartenmann; Emilio Fossali; Rodo O von Vigier; Giacomo D Simonetti; Jan Schmidtko; Alberto Edefonti; Mario G Bianchetti
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

View more
  8 in total

1.  Drug therapy in kidney disease.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

Review 2.  Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.

Authors:  Punam Mistry; Hannah Batchelor
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 3.  Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.

Authors:  Siegtraut Dorothea Herder; Ernst Weber; Almuth Winkemann; Christoph Herder; Hartmut Morck
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

4.  Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

Authors:  Rossana Baracco; Gaurav Kapur
Journal:  Patient Prefer Adherence       Date:  2011-03-17       Impact factor: 2.711

5.  Differences in taste between three polyethylene glycol preparations: a randomized double-blind study.

Authors:  Tze J Lam; Chris Jj Mulder; Richelle Jf Felt-Bersma
Journal:  Patient Prefer Adherence       Date:  2011-08-17       Impact factor: 2.711

Review 6.  Clinical utility of valsartan in treatment of children and adolescents with high blood pressure.

Authors:  Manu Kaushik; Syed M Mohiuddin
Journal:  Adolesc Health Med Ther       Date:  2011-09-19

7.  Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.

Authors:  Howard Trachtman; James W Hainer; Jennifer Sugg; Renli Teng; Jonathan M Sorof; Jerilynn Radcliffe
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

Review 8.  Antihypertensive agents: a long way to safe drug prescribing in children.

Authors:  Nida Siddiqi; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2019-11-01       Impact factor: 3.651

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.